Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.

Company profile
Ticker
CERS
Exchange
Website
CEO
William Greenman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Cerus Europe B.V. ...
IRS number
680262011
CERS stock data
Latest filings (excl ownership)
8-K
Other Events
10 Mar 23
POS AM
Prospectus update (post-effective amendment)
1 Mar 23
10-K
2022 FY
Annual report
1 Mar 23
POSASR
Automatic shelf registration (post-effective amendment)
1 Mar 23
8-K
Cerus Corporation Announces Record Fourth Quarter and Full-Year 2022
28 Feb 23
8-K
Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2022 Product Revenue and Provides Business Update
9 Jan 23
UPLOAD
Letter from SEC
4 Nov 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Cerus Corporation Announces Third Quarter Financial Results
3 Nov 22
CORRESP
Correspondence with SEC
24 Oct 22
Transcripts
CERS
Earnings call transcript
2022 Q4
28 Feb 23
CERS
Earnings call transcript
2022 Q3
3 Nov 22
CERS
Earnings call transcript
2022 Q2
4 Aug 22
CERS
Earnings call transcript
2022 Q1
6 May 22
CERS
Earnings call transcript
2021 Q4
23 Feb 22
CERS
Earnings call transcript
2021 Q3
3 Nov 21
CERS
Earnings call transcript
2021 Q2
4 Aug 21
CERS
Earnings call transcript
2021 Q1
5 May 21
CERS
Earnings call transcript
2020 Q4
26 Feb 21
CERS
Earnings call transcript
2020 Q3
29 Oct 20
Latest ownership filings
Financial summary
Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 37.36 mm | 37.36 mm | 37.36 mm | 37.36 mm | 37.36 mm | 37.36 mm |
Cash burn (monthly) | (no burn) | 1.14 mm | 4.45 mm | 3.53 mm | 585.33 k | 2.13 mm |
Cash used (since last report) | n/a | 3.07 mm | 11.98 mm | 9.50 mm | 1.58 mm | 5.75 mm |
Cash remaining | n/a | 34.29 mm | 25.37 mm | 27.86 mm | 35.78 mm | 31.61 mm |
Runway (months of cash) | n/a | 30.1 | 5.7 | 7.9 | 61.1 | 14.8 |
Institutional ownership, Q4 2022
13F holders | Current |
---|---|
Total holders | 185 |
Opened positions | 20 |
Closed positions | 20 |
Increased positions | 58 |
Reduced positions | 75 |
13F shares | Current |
---|---|
Total value | 517.74 bn |
Total shares | 145.78 mm |
Total puts | 196.50 k |
Total calls | 349.70 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Baker Bros. Advisors | 16.07 mm | $58.65 bn |
ARK Investment Management | 15.86 mm | $57.90 bn |
BLK Blackrock | 12.59 mm | $45.97 bn |
Vanguard | 10.90 mm | $39.79 bn |
Primecap Management | 8.85 mm | $32.30 bn |
CMTDF Sumitomo Mitsui Trust | 7.17 mm | $26.18 bn |
Nikko Asset Management Americas | 7.17 mm | $26.10 bn |
Senvest Management | 6.56 mm | $23.93 bn |
Wasatch Advisors | 4.86 mm | $17.76 bn |
STT State Street | 4.18 mm | $15.25 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Mar 23 | Benjamin Richard J | Common Stock | Sell | Dispose S | No | No | 2.7793 | 10,000 | 27.79 k | 347,439 |
13 Mar 23 | Benjamin Richard J | Common Stock | Sell | Dispose S | No | Yes | 2.8 | 5,747 | 16.09 k | 357,439 |
13 Mar 23 | Benjamin Richard J | Common Stock | Sell | Dispose S | No | Yes | 2.8 | 9,606 | 26.90 k | 346,519 |
13 Mar 23 | Corash Laurence M | Common Stock | Sell | Dispose S | No | Yes | 2.8 | 5,745 | 16.09 k | 2,261,501 |
13 Mar 23 | Corash Laurence M | Common Stock | Sell | Dispose S | No | Yes | 2.8 | 9,597 | 26.87 k | 2,250,579 |
13 Mar 23 | Green Kevin Dennis | Common Stock | Sell | Dispose S | No | Yes | 2.8 | 7,501 | 21.00 k | 435,963 |
13 Mar 23 | Green Kevin Dennis | Common Stock | Sell | Dispose S | No | Yes | 2.8 | 9,662 | 27.05 k | 421,797 |
13 Mar 23 | Greenman William Mariner | Common Stock | Sell | Dispose S | No | No | 2.8 | 22,732 | 63.65 k | 2,658,346 |
13 Mar 23 | Greenman William Mariner | Common Stock | Sell | Dispose S | No | No | 2.8 | 37,748 | 105.69 k | 2,616,411 |
13 Mar 23 | Menard Chrystal | Common Stock | Sell | Dispose S | No | Yes | 2.8 | 5,758 | 16.12 k | 349,530 |
News
Stocks That Hit 52-Week Lows On Wednesday
1 Mar 23
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
1 Mar 23
Cerus Q4 EPS $(0.08) Misses $(0.05) Estimate, Sales $44.03M Miss $45.96M Estimate
28 Feb 23
Earnings Scheduled For February 28, 2023
28 Feb 23
BTIG Downgrades Cerus to Neutral
20 Jan 23
Press releases
Cerus Corporation Announces Record Fourth Quarter and Full-Year 2022 Financial Results
28 Feb 23
Cerus Corporation to Release Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023
15 Feb 23
Cerus Corporation to Participate in Upcoming Investor Conferences
10 Feb 23
Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2022 Product Revenue and Provides Business Update
9 Jan 23